Skip to content

A study on the safety of concentrated liquid diet containing pectin administered by gravity administration via naso-gastric tube

A study on the safety of concentrated liquid diet containing pectin administered by gravity administration via naso-gastric tube - A study on the safety of gravity administration of concentrated liquid diet containing pectin A study on the safety of concentrated liquid diet containing pectin administered by gravity administration

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000013610
Enrollment
50
Registered
2014-04-15
Start date
2014-05-15
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients requiring the nutritional management using naso-gastric tube

Interventions

The HINE E-gel is given via a naso-gastric tube (12 Fr) by the gravity administration for a week. The daily dose calculated by the Harris-Benedict equation is divided into three administrations which

Sponsors

Joetsu general hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1)Patients who are 20 years or older at the date of informed consent 2)Patients who receive the transnasal nutrition with the catheter inserted into the stomach 3)Patients who are able to provide a voluntary consent after receiving the sufficient verbal or written explanation for participation in the study

Exclusion criteria

Exclusion criteria: 1)Patients who might have an allergy to the study product or other food 2)Patients who take gastric acid secretion inhibitor 3)Patients who might not be able to participate in the study because of complications such as hepatic failure, kidney failure, and cardiac disease 4)Female patients who are pregnant, lactating, or potentially pregnant 5)Patients who are deemed unsuitable for inclusion in the study for any other reason by the investigator

Design outcomes

Primary

MeasureTime frame
Incidence of gastrointestinal symptoms Total number of defecation and frequency of diarrhea Presence or absence of vomiting, nausea, and abdominal distention Frequency of antiflatulent usage

Secondary

MeasureTime frame
Nutritional parameters (blood albumin, total blood protein, blood trans-thyretin, and body weight)

Countries

Japan

Contacts

Public ContactSatoshi Goshi

Joetsu general hospital gastrointestinal medicine

goshi@joetsu-hp.jp025-524-3000

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026